Evogene (EVGN) has released an update.
Evogene Ltd., a computational biology company, reported increased H1 2024 revenues of $5.1M and a reduced H1 loss of $9.8M, with revenue growth expected to continue into H2. The company’s financial performance was bolstered by Casterra’s $8.0M seed orders and the commercial expansion of Lavie Bio’s bio-inoculant Yalos™. Additionally, significant R&D progress was noted, including promising Phase 1 results for Biomica’s BMC128.
For further insights into EVGN stock, check out TipRanks’ Stock Analysis page.
